Pharmaceuticals, Biotechnology and Life Sciences
Company recognized for advancing ENV‑105, a first‑in‑class resistance‑modulating antibody for metastatic castration‑resistant prostate cancer LOS ANGELES–(BUSINESS WIRE)–Kairos Pharma Ltd. (NYSE…
CAMBRIDGE, Mass. & LONDON–(BUSINESS WIRE)–Valink Therapeutics (“Valink”), a private biotechnology company developing next-generation therapeutics with a focus on bispecific antibody-drug…
SCHAUMBURG, Ill.–(BUSINESS WIRE)–Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced that it will be attending…
— Submission supported by positive preliminary 18-month NAUTILUS data in patients with drug-resistant idiopathic generalized epilepsy (IGE) and generalized tonic-clonic…
ENV-308 is a first-in-class, once-daily oral therapy designed for chronic weight management, emphasizing high-quality weight loss with muscle mass preservation…
SAN DIEGO–(BUSINESS WIRE)–Autobahn Therapeutics, a biotechnology company developing restorative treatments for people affected by neuropsychiatric and neuroimmunologic disorders, today announced…
First and only immunotherapy plus ADC regimen, used perioperatively, to extend survival for cisplatin-eligible patients with MIBC RAHWAY, N.J.–(BUSINESS WIRE)–Merck…
NEW YORK–(BUSINESS WIRE)–Kallyope, a late-stage biotechnology company leveraging unique insights into neural signaling pathways to develop innovative therapies for health…
Post-hoc analyses of the phase III ARCADIA and OLYMPIA clinical trial programs, published in the Journal of the European Academy…
– Vir Biotechnology to receive EUR 55 million initial reimbursement payment upon closing, and up to EUR 495 million in…